ICAD | iCAD, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.7200 - 1.8100
52 Week Range	1.1800 - 2.6500
Beta	1.58
Implied Volatility	245.75%
IV Rank	87.00%
Day's Volume	130,394
Average Volume	160,487
Shares Outstanding	26,540,000
Market Cap	46,179,600
Sector	Healthcare
Industry	Medical - Devices
IPO Date	1984-12-13

Valuation
Profitability
Growth
Health
P/E Ratio	-10.87
Forward P/E Ratio	-3.11
EPS	-0.16
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	67
Country	USA
Website	ICAD

icad Inc provides cancer detection, radiation therapy and workflow solutions, primarily computer-aided detection and workflow solutions for breast, prostate and colorectal cancers. Its products include powerlook tomo detection, powerlook density assessment, and vera look. The firm has also developed a technology namely Xoft Axxent electronic brachytherapy system used in the treatment of non-melanoma skin cancer, early-stage breast cancer, and gynecological cancers.

ICAD's peers: PROF, SIBN, SGHT, NVRO, FNA, SSKN, SIEN, AXGN, AIMD, LNSR, AZYO, INVO, NVNO, ESTA, CVRX, SRGA, SRDX, BMRA, MOVE

*Chart delayed

Analyzing fundamentals for ICAD we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see ICAD Fundamentals page.

Watching at ICAD technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on ICAD Technicals page.